Algeta to Participate in Upcoming Investor Conference

Algeta to Participate in Upcoming Investor Conference 
OSLO, NORWAY -- (Marketwired) -- 04/17/13 --  Algeta ASA (OSE:
ALGETA), a company focused on the
development of novel targeted
cancer therapeutics, announces that members of its senior management
and IR teams will participate in the following investor conference: 
Kempen & Co. 6(th) Healthcare/Life Sciences Conference 
Date: 23 April 2013 
Thomas Ramdahl (Chief Technology Officer) 
Renate Birkeli (IR) 
Venue: Amsterdam, The Netherlands 
About Algeta 
Algeta  is a company focused on developing novel targeted therapies
for patients
with   cancer  based  on  its  alpha-pharmaceutical 
platform.  The Company  is headquartered in Oslo, Norway, and has a
US subsidiary, Algeta US, LLC, based in Cambridge,  MA performing
commercial  marketing operations in  the US. Algeta is listed  on the
Oslo Stock Exchange (Ticker: ALGETA). For more information
Algeta to Participate in Upcoming Investor Conference: 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Algeta ASA via Thomson Reuters ONE 
For further information, please contact: 
Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs 
Media enquiries: 
Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson 
Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton 
Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications 
US investor enquiries:
Tricia Swanson
+1 646 378 2953 
The Trout Group
Press spacebar to pause and continue. Press esc to stop.